Cost‐Effectiveness Analysis of First‐Line Chemotherapy for Metastatic Pancreatic Cancer in Japan
The findings of this study suggest that S-1 is a cost-effective and promising treatment option for distant metastatic pancreatic cancer in Japan. Its favourable economic profile, combined with its safety and convenience advantages, makes it a viable choice for patients and healthcare providers.
Authors
- Yuriko Sasahara
- Manabu Akazawa (ORCID: https://orcid.org/0000-0002-4112-6035)
- Tatsunori Murata (ORCID: https://orcid.org/0000-0003-0132-5424)
- Yuki Takumoto (ORCID: https://orcid.org/0000-0001-9191-3494)
- Hiroto Narimatsu (ORCID: https://orcid.org/0000-0002-0383-4911)
Institutions
- Meiji Pharmaceutical University (JP)
- Kanagawa Prefectural Hospital Organization (JP)
- Yamagata Prefectural Central Hospital (JP)
- Kanagawa University of Human Services (JP)
Publication Details
- Journal
- Cancer Medicine
- Published
- 2025-09-01
- DOI
- https://doi.org/10.1002/cam4.71233
- Primary Topic
- Pancreatic and Hepatic Oncology Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Kanagawa University
- Japan Society for the Promotion of Science